Patents Examined by Elli Peselev
  • Processes for isolation and purification of enfumafungin
    Patent number: 8674087
    Abstract: The present disclosure relates to processes useful in the isolation and purification of enfumafungin, which is classified as a triterpene glycoside antifungal compound and acts as a glucan synthase inhibitor. Enfumafungin has application in the treatment of conditions caused by fungal infection and is also useful as an intermediate in the preparation of other compounds useful as antifungal agents and/or inhibitors of (1,3)-?-D-glucan synthesis.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: March 18, 2014
    Assignee: Scynexis, Inc.
    Inventors: Jennifer M. Pollard, Rebecca A. Chmielowski, Lisa M. Dietrich, Francis P. Gailliot, Kent Goklen
  • Combination of compounds for treating or preventing skin diseases
    Patent number: 8669233
    Abstract: A combination of compounds for treating skin diseases and particularly rosacea and ocular rosacea is described. The combination of a compound of the avermectin family or of the mylbemycin family with a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists is also described. In addition, a product in the form of a kit including: (a) a first composition containing a compound of the avermectin family or of the mylbemycin family, and (b) a second composition different from the first one and containing a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists, as a combination product to be used as a drug for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay is described.
    Type: Grant
    Filed: February 16, 2010
    Date of Patent: March 11, 2014
    Assignee: Galderma Research & Development
    Inventors: André Jomard, Laurent Fredon, Olivier Roye
  • Linker and support for solid phase synthesis of nucleic acid
    Patent number: 8669356
    Abstract: The invention provides a universal linker capable of synthesizing nucleic acid having a phosphate group at the 3? terminal, a universal support carrying the linker, and a synthesis method of nucleic acid using the universal support. The linker for solid phase synthesis of nucleic acid contains a compound represented by at least one of the following formulae wherein each symbol is as defined in the specification.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: March 11, 2014
    Assignees: Nitto Denko Corporation, National University Corporation Nagoya University
    Inventors: Yoshihiro Hayakawa, Masaki Tsukamoto, Kenjiro Mori, Kenjiro Minomi, Eri Maeta, Tatsuya Konishi
  • Methods of treatment of endobronchial infections
    Patent number: 8664187
    Abstract: The present invention provides methods for the treatment of an endobronchial infection in a patient by administering to the endobronchial system of the patient a dry powder aerosol composition comprising from 90 to 130 mg of an aminoglycoside antibiotic one to three times a day for a first treatment period of 20 to 36 days.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: March 4, 2014
    Assignee: Novartis AG
    Inventors: Peter Challoner, Carlos Rodriguez, Emil Samara, Thomas E Tarara, John D Lord
  • Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
    Patent number: 8664264
    Abstract: The present invention provides an antiproliferative compound having a structural formula where X and Y independently are oxygen, nitrogen or sulfur; R1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolacid, thiolester, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ethers or nitriles; R2 and R3 are hydrogen or R4; R4 is methyl, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzylester, saccharide or amine; and R5 is alkenyl; where when Y is nitrogen, said nitrogen is substituted with R6, wherein R6 is hydrogen or methyl. Also provided are methods for treating a cell proliferative disease and for inducing apoptosis in a cell comprising administering this compound is also provided.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: March 4, 2014
    Assignee: Research Development Foundation
    Inventors: Bob G. Sanders, Kimberly Kline, Weiping Yu
  • Stambomycin and derivatives, their production and their uses as drugs
    Patent number: 8664186
    Abstract: The present invention relates to Stambomycin compounds, their derivatives and their pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: March 4, 2014
    Assignees: Universite de Lorraine, University of Warwick, Institut National de la Recherche Agronomique
    Inventors: Bertrand Aigle, Gregory Challis, Luisa Laureti, Lijiang Song, Pierre Leblond
  • Methods for preventing or reducing neurotoxicity associated with administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
    Patent number: 8658618
    Abstract: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme in both nervous and non-nervous tissues within the patient and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU generated from a prodrug is in substantial excess of DPD inhibitor in the patient.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: February 25, 2014
    Assignee: Adherex Technologies, Inc.
    Inventor: Thomas Spector
  • Methods and formulations for reducing amphotericin B treatment side effects
    Patent number: 8648050
    Abstract: A method of ameliorating amphotericin treatment side effects in a mammal that comprises administering a therapeutically effective amount of a formulation that comprises a polyene active ingredient that includes amphotericin B, wherein the amphotericin B compound is present, in terms of polyene content, in an amount greater than 90%, and non-amphotericin B polyene compounds are present in an amount of no greater than 10%, and a pharmaceutically effective carrier; and administering a therapeutically effective amount of said formulation to a subject in need thereof.
    Type: Grant
    Filed: January 5, 2011
    Date of Patent: February 11, 2014
    Assignee: University of Mississippi
    Inventors: John D. Cleary, Stanley W. Chapman, Robert E. Kramer
  • Mixture and infusion or drink solution
    Patent number: 8642563
    Abstract: The invention relates to a mixture, wherein the mixture contains ribose, alanine and glycine. The mixture furthermore can contain glutamine and one or more of the following substances: valine, leucine, isoleucine, 5-hydroxy-tryptophan, tryptophan, cysteine, serine. Alternatively or in addition, the mixture furthermore can contain asparagine, arginine, proline and lysine. The invention furthermore relates to a mixture which contains ribose, glycine, proline, lysine, arginine and asparagine.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: February 4, 2014
    Inventor: Marianne Brøndlund
  • Mono-and disaccharide derivatives
    Patent number: 8637659
    Abstract: The present invention relates to a novel family of monosaccharide derivatives and disaccharide derivatives and to a method of preparation thereof. A mono- and disaccharide derivatives according to the invention comprises at least one fatty acid ester and may further comprise one or more anionic groups and are useful for, inter alia, medical, pharmaceutical, cosmetic and food applications.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: January 28, 2014
    Assignee: Protherics Medicines Development Limited
    Inventors: Lucas Alfonsus T. Hilgers, Anneke Georgine Blom
  • Method for the protection of trees
    Patent number: 8633167
    Abstract: The present invention provides a method for the prevention/treatment of bark beetle and/or wood borer infestation of trees comprising treatment of the tree with a composition comprising a macroyclic lactone.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: January 21, 2014
    Assignee: Syngenta Crop Protection LLC
    Inventors: Donald M Grosman, David Cox
  • Inhibitors of S-adenosyl-L-methionine decarboxylase
    Patent number: 8633168
    Abstract: Novel mechanism-based inhibitors of S-adenosyl-L-methionine decarboxylase are provided. These compounds of formula (1) inhibit the life cycle of trypanosomes, and are useful to treat subjects infected with African trypanosomes. The invention includes pharmaceutical compositions and methods of using the compounds of formula (1).
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: January 21, 2014
    Assignee: Genzyme Corporation
    Inventors: Yibin Xiang, Bradford Hirth, Cassandra Celatka
  • Forms of CDDO methyl ester
    Patent number: 8633243
    Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: January 21, 2014
    Assignee: Reata Pharmaceuticals, Inc.
    Inventors: John Walling, Stephan D. Parent, David T. Jonaitis, Robert M. Kral, Jr.
  • Isoflavones for treating mucopolysaccharidoses
    Patent number: 8623910
    Abstract: A method of treatment of mucopolysaccharidosis, the method including administering to a patient in the need of such treatment—a therapeutically effective amount of a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition including a pharmaceutically acceptable excipient; and a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof, the natural isoflavone, the derivative thereof, or the pharmaceutically acceptable salt thereof being in a therapeutically effective amount for the treatment of mucopolysaccharidosis.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: January 7, 2014
    Assignee: Instytut Farmaceutyczny
    Inventors: Grzegorz Grynkiewicz, Grzegorz Wegrzyn, Barbara Szechner, Wieslaw Szeja, Anna Tylki-Szymanska, Alicja Wegrzyn, Joanna Jakobkiewicz-Banecka, Sylwia Baranska, Barbara Czartoryska, Ewa Piotrowska
  • Hemostatic agent and method
    Patent number: 8623842
    Abstract: One aspect of the invention is a method of treating a wound to clot blood. A sponge material is applied to the wound. The sponge comprises a starch having hemostatic properties and at least one binding agent. The sponge may further comprise a porous, flexible material.
    Type: Grant
    Filed: September 26, 2007
    Date of Patent: January 7, 2014
    Assignee: Hemostasis, LLC
    Inventors: Keith A. Roberts, John Henry Burban, Majid Zia, Michael R. Spearman
  • GPCR enhanced neuroprotection to treat brain injury
    Patent number: 8618074
    Abstract: Disclosed are methods of preventing or treating neuronal damage associated with oxidative stress and/or neuronal injury. The method comprises administering to a patient a pharmaceutical composition comprising a purinergic P2Y receptor ligand, in an amount effective to increase the extracellular concentration of said agonist in the brain of the subject such that at least a portion of cell surface P2Y receptors expressed by astrocytes are activated to mount a neuroprotective response. The pharmaceutical composition may be administered orally or parenterally. The pharmaceutical composition with typically be administered to an individual within at least one hour of the event that caused oxidative stress in the subject.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: December 31, 2013
    Assignee: Board of Regents of the University of Texas System
    Inventor: James D. Lechleiter
  • Saccharide structures and methods of making and using such structures
    Patent number: 8614314
    Abstract: Described are oligosaccharides having a protecting group at two, a plurality, a majority of, or each position in the oligosaccharide which is amenable to derivatization. Collections, libraries and methods of making and using such oligosaccharides are also described.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: December 24, 2013
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Roy Sucharita, Takashi Kei Kishimoto, Ganesh Venkataraman
  • Compositions comprising at least one complex composed of a derivative of naphthoic acid and of at least one cyclodextrin and uses thereof
    Patent number: 8614199
    Abstract: A composition is described for topical application comprising, in a physiologically acceptable medium, at least one complex composed of a naphthoic acid derivative of formula (I), salts and esters thereof: and of at least one cyclodextrin, said soluble molecular complex obtained by the technology of dense fluids under pressure.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: December 24, 2013
    Assignee: Galderma Research & Development
    Inventors: Emmanuelle At, Claire Mallard
  • Methods of producing microparticles
    Patent number: 8613955
    Abstract: Methods of producing microparticles, and especially chitin microparticles (CMP), are disclosed that involve reducing the size of (larger) particles using a (high shear) microfluidising instrument.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: December 24, 2013
    Assignee: Mucovax Inc.
    Inventor: Peter Strong
  • Vitamin B12 compositions
    Patent number: 8609630
    Abstract: This disclosure provides compositions of vitamin B12, and methods of treatment or amelioration of a disease associated with vitamin B12 deficiency. The composition can take the form of a solid, semi-solid, gummy, or chewable lozenge. The composition can also take the form of a troche, a candy, a wafer, an orally disintegrating tablet, a sublingual tablet, a buccal tablet, a buccal patch, an oral dissolvable film, an aerosol or spray, a lip balm, and chewing gum.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: December 17, 2013
    Assignee: Bebaas, Inc.
    Inventor: Chad Brown